Trial Profile
An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Hairy cell leukaemia
- Focus Expanded access; Therapeutic Use
- Acronyms MOXE
- Sponsors AstraZeneca
- 03 Dec 2018 Status changed from recruiting to completed.
- 20 Apr 2018 New trial record